Nimotuzumab combo after pancreatic cancer surgery
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests adding nimotuzumab (a targeted therapy) to standard chemotherapy for people whose pancreatic cancer was completely removed with surgery. The goal is to see if this combination helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove all visible pancreatic cancer.
- Cancer has not spread to other parts of the body.
- You are in generally good health (able to do daily activities without help).
- Your liver, kidneys, bone marrow, and heart function are adequate.
- You have not previously received any treatment (like chemo or radiation) for this cancer.
- You are not allergic to the drugs used in this study.
- If you can become pregnant, you agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a targeted drug (nimotuzumab) to standard chemotherapy after surgery can help prevent pancreatic cancer from coming back. It is designed for people who have had their pancreatic cancer completely or nearly completely removed.
This trial tests two drugs, tislelizumab and SX-682, given before surgery for people with pancreatic cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial tests a new chemotherapy combination after surgery for pancreatic cancer to see if it helps prevent the cancer from coming back. It compares the new treatment to a standard one.
This trial tests if giving a combination of four drugs before and after surgery can help treat pancreatic cancer. The drugs include HRS-4642, gemcitabine, nab-paclitaxel, and adebrelimab. It may help shrink the tumor before surgery and lower the chance of cancer coming back afterward.
This trial tests combining nimotuzumab with chemotherapy (nab-paclitaxel and gemcitabine) after surgery to prevent pancreatic cancer from returning. It is for people whose tumors have a protein called EGFR, and whose cancer was removed with clear or close margins.
This trial tests a combination of drugs (nimotuzumab, nab-paclitaxel, and gemcitabine) given before and after surgery for pancreatic cancer that is either removable or borderline removable but has high-risk features. The goal is to see if this approach improves outcomes.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.